Optimal Implantable Cardioverter Defibrillator (ICD) Generator Replacement

被引:6
|
作者
Khojandi, Anahita [1 ]
Maillart, Lisa M. [1 ]
Prokopyev, Oleg A. [1 ]
Roberts, Mark S. [2 ]
Brown, Timothy [3 ]
Barrington, William W. [4 ]
机构
[1] Univ Pittsburgh, Dept Ind Engn, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA
[3] Medtronic, Minneapolis, MN 55432 USA
[4] Univ Pittsburgh, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA 15213 USA
基金
美国国家科学基金会;
关键词
optimal replacement; Markov decision processes; threshold policy; CUMULATIVE DAMAGE MODELS; FOLLOW-UP; DEVICE ADVISORIES; CLINICAL-PRACTICE; RISK-FACTORS; LONGEVITY; INFECTIONS; PACEMAKERS; INSIGHTS; DATABASE;
D O I
10.1287/ijoc.2013.0586
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Implantable cardioverter defibrillators ( ICDs) include small, battery-powered generators, the longevity of which depends on a patient's rate of consumption. Generator replacement, however, involves risks, including death. Hence, a trade-off exists between prematurely exposing the patient to these risks and allowing for the possibility that the device is unable to deliver therapy when needed. Currently, replacements are performed using a one-size-fits-all approach. Here, we develop a Markov decision process model to determine patient-specific optimal replacement policies as a function of patient age and the remaining battery capacity. We analytically establish that the optimal policy is of threshold-type in the remaining capacity, but not necessarily in patient age. Based on clinical data, we conduct a large computational study that suggests that under the optimal policy, patients undergoing initial implantation at age 30-40, 41-60, and 61-80 see an approximate decrease in the total expected number of replacements of 8%-14%, 8%-15% and 8%-19%, respectively, while achieving the same or greater expected lifetime.
引用
收藏
页码:599 / 615
页数:17
相关论文
共 50 条
  • [41] Preventing premature implantable cardioverter defibrillator therapy (ICD) by using the wearable cardioverter-defibrillator (WCD)
    Waessnig, N.
    Guenther, M.
    Quick, S.
    Wiedemann, S.
    Heidrich, F.
    Sveric, K.
    Strasser, R.
    Ibrahim, K.
    Speiser, U.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1378 - 1378
  • [42] SUBDIAPHRAGMATIC IMPLANTATION OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR GENERATOR
    OBADIA, JF
    CLAUDEL, JP
    RESCIGNO, G
    KIRKORIAN, G
    HERCULE, C
    CHASSIGNOLLE, JF
    TOUBOUL, P
    ANNALS OF THORACIC SURGERY, 1995, 59 (01): : 239 - 241
  • [43] WHEN IS IT SAFE NOT TO REPLACE AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR GENERATOR
    TCHOU, P
    AXTELL, K
    ANDERSON, AJ
    KEIM, S
    SRA, J
    TROUP, P
    JAZAYERI, M
    AVITALL, B
    AKHTAR, M
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1991, 14 (11): : 1875 - 1880
  • [44] Patients' experiences of the implantable cardioverter defibrillator (ICD) with a focus on battery replacement and end-of-life issues
    Fluur, Christina
    Bolse, Karstin
    Stromberg, Anna
    Thylen, Ingela
    HEART & LUNG, 2013, 42 (03): : 202 - 207
  • [45] Benefit of implantable cardioverter-defibrillator therapy after generator replacement in patients with Brugada syndrome
    Kim, Ju Youn
    Kim, Sung-Hwan
    Kim, Sung Su
    Lee, Ki Hong
    Park, Hyung-Wook
    Cho, Jeong-Gwan
    Uhm, Jae-Sun
    Joung, Boyoung
    Pak, Hui-Nam
    Lee, Moon-Hyoung
    Park, Seung-Jung
    On, Young Keun
    Kim, June Soo
    Lim, Hong Euy
    Shim, Jaemin
    Choi, Jong-Il
    Park, Sang Weon
    Kim, Young-Hoon
    Lee, Woo Seok
    Kim, Jun
    Nam, Gi-Byoung
    Choi, Kee-Joon
    Kim, You-Ho
    Oh, Yong-Seog
    Lee, Man-Young
    Rho, Tai-Ho
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 187 : 340 - 344
  • [46] Benefit of implantable cardioverter-defibrillator therapy after generator replacement in patients with Brugada syndrome
    Kim, S. H.
    Kim, J. Y.
    Cho, J. G.
    Lee, M. H.
    Kim, J. S.
    Kim, Y. H.
    Kim, Y. H.
    Oh, Y. S.
    Lee, M. Y.
    Rho, T. H.
    EUROPEAN HEART JOURNAL, 2015, 36 : 42 - 42
  • [47] Association between the Charlson comorbidity index and outcomes after implantable cardioverter defibrillator generator replacement
    Amin, Mustapha M.
    Witt, Chance M.
    Waks, Jonathan W.
    Mehta, Ramila A.
    Friedman, Paul A.
    Kramer, Daniel B.
    Buxton, Alfred E.
    Mulpuru, Siva K.
    Hodge, David O.
    Frey, Rebecca J.
    Frederick, Nicolette K.
    Cha, Yong-Mei
    Brenes-Salazar, Jorge
    Madhavan, Malini
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2019, 42 (09): : 1236 - 1242
  • [48] Determinants of the quality of life (QoL) in patients with an implantable cardioverter/defibrillator (ICD)
    F. Godemann
    C. Butter
    F. Lampe
    M. Linden
    S. Werner
    S. Behrens
    Quality of Life Research, 2004, 13 : 411 - 416
  • [49] Determinants of the quality of life (QoL) in patients with an implantable cardioverter/defibrillator (ICD)
    Godemann, F
    Butter, C
    Lampe, F
    Linden, M
    Werner, S
    Behrens, S
    QUALITY OF LIFE RESEARCH, 2004, 13 (02) : 411 - 416
  • [50] PACEMAKER AND IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) DEACTIVATION NEAR END OF LIFE
    Mcloughlin, P.
    Taylor, A.
    Doelman, L.
    CANADIAN JOURNAL OF CARDIOLOGY, 2012, 28 (05) : S423 - S423